Magazine Article | March 1, 2019

A Biotech's Guide To Selecting CDMOs: "35 Or 6 To 2"

Source: Life Science Leader

By Louis Garguilo, Chief Editor, Outsourced Pharma

No disrespect meant to Tom Bliss, veteran pharma and bio executive (e.g., Amgen, Baxter, Kyocera) and most recently CEO of platform-biotech Genisphere, nor James Kadushin, 22-year veteran and (retiring) VP operations/COO at the company, but as I spoke to them recently, I kept recalling Chicago’s iconic ‘70s rock song, “25 or 6 to 4.”

That’s because Bliss and Kadushin were detailing for me how Genisphere went from an original list of “35 or 6 candidate CDMOs to 2 selected” as their development and manufacturing partners. Their description of that process should be music to the ears of any biopharma undergoing or about to go on a CDMO search.